Latest On CytomX Therapeutics, Inc (CTMX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-10 01:40 EST | News | CytomX GAAP EPS of -$0.05 beats by $0.06, revenue of $23.5M beats by $3.59M | N/A |  |
| 2023-05-10 01:40 EST | News | CytomX Therapeutics, Inc. (CTMX) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-08 22:39 EST | News | CytomX Q1 2023 Earnings Preview | N/A | |
| 2023-03-28 20:35 EST | News | CytomX slumps ~15% amid FY22 miss, AbbVie pulls plug on CX-2029 studies | N/A | |
| 2023-03-28 05:02 EST | News | CytomX GAAP EPS of -$1.51 misses by $0.24, revenue of $53.16M misses by $18.91M | N/A | |
| 2023-03-28 05:02 EST | News | CytomX Therapeutics, Inc. (CTMX) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-26 22:50 EST | News | CytomX Q4 2022 Earnings Preview | N/A | |
| 2023-01-26 19:27 EST | News | CytomX stock rises as Astellas to pay $5M milestone under research pact | N/A | |
| 2023-01-20 16:52 EST | News | CytomX Therapeutics (CTMX) Presents at the 41st Annual J.P. Morgan Healthcare Conference - Slideshow | N/A | |
| 2023-01-05 21:53 EST | News | CytomX shares soar +50% on collaboration with Moderna to make mRNA-based therapies (update) | N/A | |
| 2022-11-17 19:43 EST | News | CytomX surges 26% on license deal with Regeneron to develop cancer drugs | N/A | |
| 2022-11-09 04:24 EST | News | CytomX GAAP EPS of -$0.35 misses by $0.05, revenue of $16.92M misses by $3.13M | N/A | |
| 2022-11-09 04:24 EST | News | CytomX Therapeutics, Inc. (CTMX) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-08 10:31 EST | News | CytomX Q3 2022 Earnings Preview | N/A | |
| 2022-08-06 08:07 EST | News | CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-05 01:24 EST | News | CytomX GAAP EPS of -$0.37 misses by $0.02, revenue of $18.17M misses by $0.21M | N/A | |
| 2022-08-03 19:17 EST | News | CytomX Q2 2022 Earnings Preview | N/A | |
| 2022-07-14 04:42 EST | News | CytomX Therapeutics to cut workforce by about 40% | N/A | |
| 2022-07-07 11:13 EST | News | CytomX downgraded at several Street firms following breast cancer therapy results | N/A | |
| 2022-07-06 20:52 EST | News | CytomX shares plummet 28% on phase 2 study of breast cancer antibody praluzatamab | N/A | |
| 2022-06-25 00:13 EST | News | CytomX stock rises after BMO Capital starts with Outperform rating | N/A | |
| 2022-05-26 10:06 EST | News | CytomX begins dosing in early-stage study of CX-904 for advanced solid tumors | N/A | |
| 2022-05-07 18:59 EST | News | CytomX Therapeutics' (CTMX) CEO Sean McCarthy on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-06 01:39 EST | News | CytomX GAAP EPS of -$0.37 misses by $0.01, revenue of $17.13M misses by $4.12M | N/A | |
| 2022-05-05 01:52 EST | News | CytomX Q1 2022 Earnings Preview | N/A | |
| 2022-03-04 21:13 EST | News | CytomX Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-03-02 15:41 EST | News | CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-02 15:41 EST | News | CytomX stock soars 16% as Q4 revenue rises 20% Y/Y | N/A | |
| 2022-03-01 23:24 EST | News | CytomX GAAP EPS of -$1.30 misses by $0.13, revenue of $69.57M misses by $5.85M | N/A | |
| 2022-01-20 02:47 EST | News | CytomX rises 7% on FDA nod for phase 1 trial of CX-904 to treat solid tumors | N/A | |
| 2021-12-21 00:44 EST | News | CytomX Therapeutics falls 28% on interim mid-stage results on cancer candidate | N/A | |
| 2021-12-15 08:40 EST | News | CytomX: Pullbacks Are Opportunities | N/A | |
| 2021-11-07 12:12 EST | News | CytomX Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation | N/A | |
| 2021-11-07 12:12 EST | News | CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-05 03:59 EST | News | CytomX EPS beats by $0.65, misses on revenue | N/A | |
| 2021-11-04 06:53 EST | News | CytomX Q3 2021 Earnings Preview | N/A | |
| 2021-09-21 15:32 EST | News | CytomX: Solving A Critical Problem In The High-Value ADC Space | N/A | |
| 2021-08-14 08:14 EST | News | CytomX Therapeutics (CTMX) Investor Presentation - Slideshow | N/A | |
| 2021-08-08 10:40 EST | News | CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-06 00:59 EST | News | CytomX EPS in-line, misses on revenue | N/A | |
| 2021-07-21 03:19 EST | News | Iterum keeps rising even as RBC analyst cautions, Premier hurt by Barclays’ double downgrade; and more in today’s analyst action | N/A | |
| 2021-07-21 03:05 EST | News | Checking In On CytomX Therapeutics | N/A | |
| 2021-05-07 06:27 EST | News | CytomX EPS beats by $0.06, misses on revenue | N/A | |
| 2021-02-26 03:27 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-25 03:28 EST | Earnings Estimate | An EPS average of -$2.27 is estimated for the 2022 year. | Sell | |
| 2021-02-25 03:28 EST | Earnings Estimate | An EPS average of -$0.41 is estimated for the quarter ending on June 30, 2021. | Sell | |
| 2021-02-25 00:47 EST | News | CytomX beats on revenue | N/A | |
| 2021-02-25 00:47 EST | News | CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-01-21 07:47 EST | News | CytomX Therapeutics secures $100M capital raise | N/A | |
| 2021-01-20 01:57 EST | News | CytomX Therapeutics -3% AH, proposes public offering | N/A | |
About CytomX Therapeutics, Inc (CTMX):
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
General
- Name CytomX Therapeutics, Inc
- Symbol CTMX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 144
- Fiscal Year EndDecember
- IPO Date2015-10-08
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.cytomx.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 3.89
- Price/Book (Most Recent Quarter) 11
- Enterprise Value Revenue 2.56
- Enterprise Value EBITDA 0.14
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.57
- Next Year EPS Estimate -$1.95
- Next Quarter EPS Estimate -$0.38
- Profit Margin -33%
- Operating Margin -48%
- Return on Assets -9%
- Return on Equity -65%
- Revenue 100.36 million
- Earnings Per Share -$2.20
- Revenue Per Share $2.18
- Gross Profit 100.36 million
- Quarterly Earnings Growth 97.8%
View More
Highlights
- Market Capitalization 520.87 million
- EBITDA -94456000
- PE Ratio -190.46
- PEG Ratio -1.8
- Analyst Target Price $12.56
- Book Value Per Share $1.03
View More
Share Statistics
- Shares Outstanding 64.78 million
- Shares Float 54.81 million
- % Held by Insiders 289%
- % Held by Institutions 83.5%
- Shares Short 3.33 million
- Shares Short Prior Month 3.33 million
- Short Ratio 3.15
- Short % of Float 5%
- Short % of Shares Outstanding 5%
View More
Technicals
- Beta 0.61
- 52 Week High $15.44
- 52 Week Low $4.66
- 50 Day Moving Average 8.18
- 200 Day Moving Average 7.39
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
CytomX Therapeutics, Inc (CTMX) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
CytomX Therapeutics, Inc (CTMX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-24 | $N/A | -$0.31 | -$0.50 | 38.49% |
| 2020-09-30 | 2020-11-05 | $N/A | -$0.32 | -$0.43 | 25.29% |
| 2020-06-30 | 2020-08-06 | $N/A | -$0.34 | $0.49 | -169.86% |
| 2020-03-31 | 2020-05-07 | $49.59 million | $0.26 | -$0.40 | 164.53% |
| 2019-12-31 | 2020-02-27 | $8.28 million | -$0.79 | -$0.49 | -61.22% |
| 2019-09-30 | 2019-11-07 | $10.71 million | -$0.52 | -$0.52 | -0.56% |
| 2019-06-30 | 2019-08-07 | $9.01 million | -$0.64 | -$0.54 | -19.25% |
| 2019-03-31 | 2019-05-09 | $29.49 million | -$0.31 | -$0.55 | 43.38% |
| 2018-12-31 | 2019-02-27 | $11.47 million | -$0.74 | -$0.43 | -70.39% |
| 2018-09-30 | 2018-11-06 | $12.51 million | -$0.53 | -$0.44 | -19.56% |
| 2018-06-30 | 2018-08-08 | $21.34 million | -$0.35 | -$0.44 | 19.54% |
| 2018-03-31 | 2018-05-09 | $14.18 million | -$0.40 | -$0.34 | -16.18% |
| 2017-12-31 | 2018-03-07 | $27.07 million | $0.03 | -$0.29 | 110.49% |
| 2017-09-30 | 2017-11-07 | $24.15 million | -$0.28 | -$0.31 | 9.68% |
| 2017-06-30 | 2017-08-07 | $8.75 million | -$0.69 | -$0.37 | -87.5% |
| 2017-03-31 | 2017-05-05 | $11.65 million | -$0.23 | -$0.44 | 47.49% |
| 2016-12-31 | 2017-03-02 | $6.27 million | -$0.39 | -$0.42 | 6.59% |
| 2016-09-30 | 2016-11-03 | $3.45 million | -$0.40 | -$0.31 | -30.42% |
| 2016-06-30 | 2016-08-03 | $3.09 million | -$0.39 | -$0.46 | 14.6% |
| 2016-03-31 | 2016-05-06 | $2.22 million | -$0.44 | -$0.26 | -72.55% |
| 2015-12-31 | 2016-03-07 | $1.99 million | -$0.39 | -$0.34 | -14.71% |
| 2015-09-30 | 2015-10-14 | $1.94 million | -$14.26 | -$0.25 | -5604% |
CytomX Therapeutics, Inc (CTMX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
CytomX Therapeutics, Inc (CTMX) Chart:
CytomX Therapeutics, Inc (CTMX) News:
Below you will find a list of latest news for CytomX Therapeutics, Inc (CTMX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
CytomX Therapeutics, Inc (CTMX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0.05 | CALL | 0 | 1702 | 154.58 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0.05 | CALL | 0 | 5 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0.55 | PUT | 0 | 66 | 102.11 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0 | PUT | 0 | 0 | 456.12 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 538.01 | TRUE | 0 | 0 |
| 2024-06-21 | 2.5 | 0.5 | CALL | 0 | 3 | 204.8 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2.5 | 0.9 | PUT | 0 | 0 | 91.83 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0 | PUT | 0 | 0 | 244.8 | TRUE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | PUT | 0 | 0 | 344.25 | TRUE | 0 | 0 |
| 2024-08-16 | 2.5 | 0.25 | CALL | 0 | 395 | 137.47 | FALSE | 0 | 0 |
| 2024-08-16 | 5 | 0.05 | CALL | 0 | 121 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 7.5 | 0.05 | CALL | 0 | 2 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 2.5 | 0.7 | PUT | 0 | 6 | 112.46 | TRUE | 0 | 0 |
| 2024-08-16 | 5 | 0 | PUT | 0 | 0 | 181.19 | TRUE | 0 | 0 |
| 2024-08-16 | 7.5 | 0 | PUT | 0 | 0 | 254.02 | TRUE | 0 | 0 |
| 2024-11-15 | 2.5 | 0.25 | CALL | 0 | 3 | 95.87 | FALSE | 0 | 0 |
| 2024-11-15 | 5 | 0.15 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 2.5 | 0.8 | PUT | 0 | 7 | 150.57 | TRUE | 0 | 0 |
| 2024-11-15 | 5 | 0 | PUT | 0 | 0 | 187.52 | TRUE | 0 | 0 |
| 2024-11-15 | 7.5 | 0 | PUT | 0 | 0 | 199.12 | TRUE | 0 | 0 |
| 2032-10-21 | 5 | 0.05 | CALL | 1 | 6 | 0 | FALSE | 0 | 0 |
Latest CTMX Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:58 PM EST | 4 | $1.75 |
| Jun 13, 2022 7:58 PM EST | 100 | $1.75 |
| Jun 13, 2022 7:58 PM EST | 14 | $1.74 |
| Jun 13, 2022 7:59 PM EST | 66 | $1.75 |
| Jun 13, 2022 7:59 PM EST | 100 | $1.745 |
CytomX Therapeutics, Inc (CTMX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312520176532/0001193125-20-176532-index.htm |
| 2020-04-29 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1501989/000000000020003688/0000000000-20-003688-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1501989/000008025519002692/0000080255-19-002692-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1501989/000008025520001289/0000080255-20-001289-index.htm |
| 2019-02-04 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1501989/000021545719003156/0000215457-19-003156-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1501989/000031506619000973/0000315066-19-000973-index.htm |
| 2019-04-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1501989/000031506619001491/0000315066-19-001491-index.htm |
| 2020-02-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1501989/000083423720005271/0000834237-20-005271-index.htm |
| 2019-02-12 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1501989/000090221919000110/0000902219-19-000110-index.htm |
| 2020-01-27 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1501989/000090221920000074/0000902219-20-000074-index.htm |
| 2020-03-06 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1501989/000092189520000679/0000921895-20-000679-index.htm |
| 2020-01-31 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1501989/000104018820000077/0001040188-20-000077-index.htm |
| 2020-02-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1501989/000110465920016389/0001104659-20-016389-index.htm |
| 2018-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000114036118031328/0001140361-18-031328-index.htm |
| 2018-07-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000114036118031810/0001140361-18-031810-index.htm |
| 2018-07-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000114036118031945/0001140361-18-031945-index.htm |
| 2018-08-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000114036118035277/0001140361-18-035277-index.htm |
| 2019-04-26 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1501989/000114036119007688/0001140361-19-007688-index.htm |
| 2019-04-26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1501989/000114036119007690/0001140361-19-007690-index.htm |
| 2020-04-17 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1501989/000114036120009192/0001140361-20-009192-index.htm |
| 2020-04-29 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1501989/000114036120010142/0001140361-20-010142-index.htm |
| 2020-04-29 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1501989/000114036120010147/0001140361-20-010147-index.htm |
| 2018-07-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312518215419/0001193125-18-215419-index.htm |
| 2018-07-10 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1501989/000119312518215425/0001193125-18-215425-index.htm |
| 2018-07-13 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1501989/000119312518217946/0001193125-18-217946-index.htm |
| 2018-07-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312518219686/0001193125-18-219686-index.htm |
| 2018-12-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312518353898/0001193125-18-353898-index.htm |
| 2019-01-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312519023949/0001193125-19-023949-index.htm |
| 2019-02-06 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1501989/000119312519029601/0001193125-19-029601-index.htm |
| 2019-02-08 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1501989/000119312519032241/0001193125-19-032241-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1501989/000119312519037944/0001193125-19-037944-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1501989/000119312519040972/0001193125-19-040972-index.htm |
| 2019-02-27 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1501989/000119312519054171/0001193125-19-054171-index.htm |
| 2019-03-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312519085264/0001193125-19-085264-index.htm |
| 2019-04-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312519100706/0001193125-19-100706-index.htm |
| 2019-04-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312519113391/0001193125-19-113391-index.htm |
| 2019-05-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312519158784/0001193125-19-158784-index.htm |
| 2019-06-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312519178790/0001193125-19-178790-index.htm |
| 2019-06-21 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312519178811/0001193125-19-178811-index.htm |
| 2019-08-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312519226958/0001193125-19-226958-index.htm |
| 2019-08-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312519234035/0001193125-19-234035-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1501989/000119312520038279/0001193125-20-038279-index.htm |
| 2020-02-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312520043696/0001193125-20-043696-index.htm |
| 2020-02-27 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1501989/000119312520052872/0001193125-20-052872-index.htm |
| 2020-02-27 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1501989/000119312520053023/0001193125-20-053023-index.htm |
| 2020-03-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312520082679/0001193125-20-082679-index.htm |
| 2020-03-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312520083210/0001193125-20-083210-index.htm |
| 2020-03-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312520090977/0001193125-20-090977-index.htm |
| 2020-04-28 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1501989/000119312520122043/0001193125-20-122043-index.htm |
| 2020-04-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312520123071/0001193125-20-123071-index.htm |
| 2020-05-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312520155943/0001193125-20-155943-index.htm |
| 2020-06-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312520176532/0001193125-20-176532-index.htm |
| 2020-10-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000119312520264740/0001193125-20-264740-index.htm |
| 2018-08-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1501989/000156459018020448/0001564590-18-020448-index.htm |
| 2018-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000156459018020463/0001564590-18-020463-index.htm |
| 2018-10-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000156459018024564/0001564590-18-024564-index.htm |
| 2018-11-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1501989/000156459018027387/0001564590-18-027387-index.htm |
| 2018-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000156459018027403/0001564590-18-027403-index.htm |
| 2018-11-06 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1501989/000156459018027415/0001564590-18-027415-index.htm |
| 2019-02-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000156459019004252/0001564590-19-004252-index.htm |
| 2019-02-27 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1501989/000156459019004890/0001564590-19-004890-index.htm |
| 2019-02-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000156459019004900/0001564590-19-004900-index.htm |
| 2019-05-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1501989/000156459019017968/0001564590-19-017968-index.htm |
| 2019-05-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000156459019017981/0001564590-19-017981-index.htm |
| 2019-08-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1501989/000156459019030054/0001564590-19-030054-index.htm |
| 2019-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000156459019030064/0001564590-19-030064-index.htm |
| 2019-11-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1501989/000156459019041726/0001564590-19-041726-index.htm |
| 2019-11-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000156459019041743/0001564590-19-041743-index.htm |
| 2020-02-27 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1501989/000156459020007395/0001564590-20-007395-index.htm |
| 2020-02-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000156459020007430/0001564590-20-007430-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1501989/000156459020022844/0001564590-20-022844-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000156459020022870/0001564590-20-022870-index.htm |
| 2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1501989/000156459020037722/0001564590-20-037722-index.htm |
| 2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000156459020037749/0001564590-20-037749-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1501989/000156459020051302/0001564590-20-051302-index.htm |
| 2020-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1501989/000156459020051317/0001564590-20-051317-index.htm |
| 2018-09-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761918002231/0001567619-18-002231-index.htm |
| 2018-09-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761918002232/0001567619-18-002232-index.htm |
| 2018-10-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761918003477/0001567619-18-003477-index.htm |
| 2018-11-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761918005081/0001567619-18-005081-index.htm |
| 2018-11-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761918005082/0001567619-18-005082-index.htm |
| 2018-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761918007414/0001567619-18-007414-index.htm |
| 2018-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761918007415/0001567619-18-007415-index.htm |
| 2018-12-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761918008005/0001567619-18-008005-index.htm |
| 2018-12-27 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761918008730/0001567619-18-008730-index.htm |
| 2018-12-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761918008731/0001567619-18-008731-index.htm |
| 2019-01-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919001862/0001567619-19-001862-index.htm |
| 2019-01-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919001863/0001567619-19-001863-index.htm |
| 2019-01-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919001864/0001567619-19-001864-index.htm |
| 2019-01-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919001865/0001567619-19-001865-index.htm |
| 2019-01-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919001866/0001567619-19-001866-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919006113/0001567619-19-006113-index.htm |
| 2019-04-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919008682/0001567619-19-008682-index.htm |
| 2019-05-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919009690/0001567619-19-009690-index.htm |
| 2019-05-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919009691/0001567619-19-009691-index.htm |
| 2019-05-10 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919010365/0001567619-19-010365-index.htm |
| 2019-05-31 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919012520/0001567619-19-012520-index.htm |
| 2019-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919012666/0001567619-19-012666-index.htm |
| 2019-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919012669/0001567619-19-012669-index.htm |
| 2019-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919012671/0001567619-19-012671-index.htm |
| 2019-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919013822/0001567619-19-013822-index.htm |
| 2019-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919013823/0001567619-19-013823-index.htm |
| 2019-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919013824/0001567619-19-013824-index.htm |
| 2019-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919013825/0001567619-19-013825-index.htm |
| 2019-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919013826/0001567619-19-013826-index.htm |
| 2019-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919013827/0001567619-19-013827-index.htm |
| 2019-10-16 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919019674/0001567619-19-019674-index.htm |
| 2019-10-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919019675/0001567619-19-019675-index.htm |
| 2019-12-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761919023150/0001567619-19-023150-index.htm |
| 2020-02-05 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920002229/0001567619-20-002229-index.htm |
| 2020-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920002230/0001567619-20-002230-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920004345/0001567619-20-004345-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920004346/0001567619-20-004346-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920004347/0001567619-20-004347-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920004348/0001567619-20-004348-index.htm |
| 2020-02-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920004554/0001567619-20-004554-index.htm |
| 2020-03-25 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920006995/0001567619-20-006995-index.htm |
| 2020-03-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920006996/0001567619-20-006996-index.htm |
| 2020-04-29 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920008616/0001567619-20-008616-index.htm |
| 2020-04-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920008617/0001567619-20-008617-index.htm |
| 2020-05-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920010115/0001567619-20-010115-index.htm |
| 2020-06-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920011542/0001567619-20-011542-index.htm |
| 2020-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920012298/0001567619-20-012298-index.htm |
| 2020-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920012299/0001567619-20-012299-index.htm |
| 2020-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920012300/0001567619-20-012300-index.htm |
| 2020-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920012301/0001567619-20-012301-index.htm |
| 2020-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920012304/0001567619-20-012304-index.htm |
| 2020-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920012361/0001567619-20-012361-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920012433/0001567619-20-012433-index.htm |
| 2020-09-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1501989/000156761920017051/0001567619-20-017051-index.htm |
| 2019-02-11 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1501989/999999999519000158/9999999995-19-000158-index.htm |
| 2018-11-19 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1501989/999999999718009035/9999999997-18-009035-index.htm |
| 2018-11-19 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1501989/999999999718009038/9999999997-18-009038-index.htm |
CytomX Therapeutics, Inc (CTMX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of CytomX Therapeutics, Inc (CTMX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 289%Institutional Ownership: 8350%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-21 | Sean A. McCarthy | President and CEO | Buy | 20,500.00 | 6.61 | 135,601.35 | 105,964.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761920017051/0001567619-20-017051-index.htm |
| 2019-05-31 | LLOYD A ROWLAND | General Counsel | Buy | 1,812.00 | 8.21 | 14,878.33 | 11,791.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761919012671/0001567619-19-012671-index.htm |
| 2020-05-12 | Sean A. McCarthy | President and CEO | Buy | 36,000.00 | 1.13 | 40,820.40 | 120,306.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761920010115/0001567619-20-010115-index.htm |
| 2019-05-31 | Robin Knifsend | Principal Accounting Officer | Buy | 1,812.00 | 8.21 | 14,878.33 | 2,791.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761919012669/0001567619-19-012669-index.htm |
| 2018-07-02 | DEBANJAN RAY | Chief Financial Officer | Sell | 3,000.00 | 22.56 | 67,680.00 | 5,928.00 | https://www.sec.gov/Archives/edgar/data/1501989/000114036118031328/0001140361-18-031328-index.htm |
| 2018-08-01 | DEBANJAN RAY | Chief Financial Officer | Sell | 3,000.00 | 26.05 | 78,150.00 | 5,928.00 | https://www.sec.gov/Archives/edgar/data/1501989/000114036118035277/0001140361-18-035277-index.htm |
| 2018-09-04 | DEBANJAN RAY | Chief Financial Officer | Sell | 3,000.00 | 22.39 | 67,170.00 | 5,928.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761918002232/0001567619-18-002232-index.htm |
| 2018-10-01 | DEBANJAN RAY | Chief Financial Officer | Sell | 3,000.00 | 18.46 | 55,380.00 | 5,928.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761918003477/0001567619-18-003477-index.htm |
| 2018-11-01 | DEBANJAN RAY | Chief Financial Officer | Sell | 3,000.00 | 15.00 | 45,000.00 | 5,928.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761918005082/0001567619-18-005082-index.htm |
| 2018-12-12 | DEBANJAN RAY | Chief Financial Officer | Sell | 3,000.00 | 15.00 | 45,000.00 | 5,928.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761918008005/0001567619-18-008005-index.htm |
| 2018-07-03 | Sean A. McCarthy | President and CEO | Sell | 2,028.00 | 25.09 | 50,880.49 | 82,063.00 | https://www.sec.gov/Archives/edgar/data/1501989/000114036118031810/0001140361-18-031810-index.htm |
| 2018-07-05 | Sean A. McCarthy | President and CEO | Sell | 4,497.00 | 25.06 | 112,688.52 | 82,063.00 | https://www.sec.gov/Archives/edgar/data/1501989/000114036118031945/0001140361-18-031945-index.htm |
| 2018-09-04 | Sean A. McCarthy | President and CEO | Sell | 13,052.00 | 21.86 | 285,342.82 | 82,063.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761918002231/0001567619-18-002231-index.htm |
| 2018-11-01 | Sean A. McCarthy | President and CEO | Sell | 5,270.00 | 15.00 | 79,050.00 | 82,063.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761918005081/0001567619-18-005081-index.htm |
| 2018-11-02 | Sean A. McCarthy | President and CEO | Sell | 1,156.00 | 15.01 | 17,348.09 | 82,063.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761918005081/0001567619-18-005081-index.htm |
| 2018-11-30 | Sean A. McCarthy | President and CEO | Buy | 468.00 | 11.73 | 5,489.64 | 82,531.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761918007415/0001567619-18-007415-index.htm |
| 2018-11-02 | Sean A. McCarthy | President and CEO | Buy | 1,156.00 | 1.57 | 1,820.58 | 83,219.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761918005081/0001567619-18-005081-index.htm |
| 2019-05-31 | Sean A. McCarthy | President and CEO | Buy | 695.00 | 8.21 | 5,706.65 | 83,226.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761919012666/0001567619-19-012666-index.htm |
| 2018-07-03 | Sean A. McCarthy | President and CEO | Buy | 2,028.00 | 1.57 | 3,193.90 | 84,091.00 | https://www.sec.gov/Archives/edgar/data/1501989/000114036118031810/0001140361-18-031810-index.htm |
| 2019-11-30 | Sean A. McCarthy | President and CEO | Buy | 1,080.00 | 5.32 | 5,746.68 | 84,306.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761919023150/0001567619-19-023150-index.htm |
| 2020-05-12 | Sean A. McCarthy | President and CEO | Sell | 36,000.00 | 15.00 | 540,000.00 | 84,306.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761920010115/0001567619-20-010115-index.htm |
| 2020-05-29 | Sean A. McCarthy | President and CEO | Buy | 1,158.00 | 5.11 | 5,915.64 | 85,464.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761920011542/0001567619-20-011542-index.htm |
| 2018-08-01 | DEBANJAN RAY | Chief Financial Officer | Buy | 2,710.00 | 1.26 | 3,414.33 | 8,638.00 | https://www.sec.gov/Archives/edgar/data/1501989/000114036118035277/0001140361-18-035277-index.htm |
| 2018-07-05 | Sean A. McCarthy | President and CEO | Buy | 4,497.00 | 1.57 | 7,082.33 | 86,560.00 | https://www.sec.gov/Archives/edgar/data/1501989/000114036118031945/0001140361-18-031945-index.htm |
| 2018-11-01 | Sean A. McCarthy | President and CEO | Sell | 100.00 | 15.01 | 1,500.50 | 87,333.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761918005081/0001567619-18-005081-index.htm |
| 2018-11-01 | Sean A. McCarthy | President and CEO | Buy | 5,370.00 | 1.57 | 8,457.21 | 87,433.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761918005081/0001567619-18-005081-index.htm |
| 2018-07-02 | DEBANJAN RAY | Chief Financial Officer | Buy | 3,000.00 | 1.26 | 3,779.70 | 8,928.00 | https://www.sec.gov/Archives/edgar/data/1501989/000114036118031328/0001140361-18-031328-index.htm |
| 2018-08-01 | DEBANJAN RAY | Chief Financial Officer | Buy | 290.00 | 1.45 | 420.18 | 8,928.00 | https://www.sec.gov/Archives/edgar/data/1501989/000114036118035277/0001140361-18-035277-index.htm |
| 2018-09-04 | DEBANJAN RAY | Chief Financial Officer | Buy | 3,000.00 | 1.45 | 4,346.70 | 8,928.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761918002232/0001567619-18-002232-index.htm |
| 2018-10-01 | DEBANJAN RAY | Chief Financial Officer | Buy | 3,000.00 | 1.45 | 4,346.70 | 8,928.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761918003477/0001567619-18-003477-index.htm |
| 2018-11-01 | DEBANJAN RAY | Chief Financial Officer | Buy | 3,000.00 | 1.45 | 4,346.70 | 8,928.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761918005082/0001567619-18-005082-index.htm |
| 2018-12-12 | DEBANJAN RAY | Chief Financial Officer | Buy | 3,000.00 | 1.45 | 4,346.70 | 8,928.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761918008005/0001567619-18-008005-index.htm |
| 2018-09-04 | Sean A. McCarthy | President and CEO | Buy | 13,052.00 | 1.57 | 20,555.59 | 95,115.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761918002231/0001567619-18-002231-index.htm |
| 2018-11-30 | LLOYD A ROWLAND | General Counsel | Buy | 979.00 | 11.73 | 11,483.67 | 979.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761918007414/0001567619-18-007414-index.htm |
| 2019-03-04 | LLOYD A ROWLAND | General Counsel | Buy | 9,000.00 | 10.33 | 92,970.00 | 9,979.00 | https://www.sec.gov/Archives/edgar/data/1501989/000156761919006113/0001567619-19-006113-index.htm |